A customer in (b)(6) reported discrepant results in association with the vitek® ms instrument.The customer stated an isolate from a patient urine sample was first identified with the vitek ms as citrobacter koseri 99.9%, and then as citrobacter sedlakii 99.9% when repeated.The customer stated that reporting was delayed because of esbl (extended spectrum beta-lactamase) confirmation, and that there was no impact to patient treatment.There is no indication or report from the hospital or treating physician to biomérieux that the discrepant result led to any adverse event related to the patient's state of health.A biomérieux internal investigation will be initiated.
|
A customer in canada reported discrepant results in association with the vitek® ms instrument.The customer stated an isolate from a patient urine sample was first identified with the vitek ms as citrobacter koseri 99.9%, and then as citrobacter sedlakii 99.9% when repeated.The expected identification is not known.An internal biomérieux investigation was opened.The customer was contacted multiple times in an effort to attain information to assist with an investigation.The customer did not provide any further information, nor was the strain submitted for investigation.Since the customer did not provide additional information or the strain for investigation, it was not possible to investigate this case to find the root cause of the issue.
|